Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 15, 2017, Pages 1460-1470

  Davies, Melanie ^a   Pieber, Thomas R ^b   Hartoft Nielsen, Marie Louise ^c   Hansen, Oluf K H ^c   Jabbour, Serge ^d   Rosenstock, Julio ^e  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c NOVO NORDISK A S   (Denmark)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Dallas Diabetes and Endocrine Center at Medical City   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PLACEBO; SEMAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPEPSIA; ERUCTATION; ETHNICITY; FEMALE; GASTROESOPHAGEAL REFLUX; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NAUSEA;

EID: 85031850914     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.14752     Document Type: Article

References (20)

1. Alani AW, Robinson JR. Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative. Pharm Res. 2008;25(1):48-54.
2. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: Mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15-27.
3. Potts JE, Gray LJ, Brady EM, Khunti K, DaviesMJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: A systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10(6): E0126769.
4. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515-520.
5. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
6. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488.
7. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4):311-322.
8. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
9. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26(1):231-238.
10. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
11. European Medicines Agency. ICH Topic E6(R1): Guideline for good clinical practice (CPMP/ICH/135/95). 2002.
12. US Government Publishing Office. Electronic Code of Federal Regulations. 2015; https://www.ecfr.gov/cgi-bin/text-idx?SID =3ee286332416f26a91d9e6d786a604ab&mc =true&tpl=/ecfrbrowse/Title21/21tab-02.tpl. Accessed June 6, 2017.
13. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: Mechanistic studies. Curr Drug Deliv. 2005;2(2):191-197.
14. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36 (5):1384-1395.
15. Medical Dictionary for Regulatory Activities. Introductory guide to MedDRA, version 17.1. 2014; https://www.meddra.org/sites/default/files /guidance/file/intguide-17-1-english.pdf. Accessed August 23, 2017.
16. Meier JJ, Rosenstock J. Therapy: Gastrointestinal safety of incretin therapies: Are we there yet?. Nat Rev Gastroenterol Hepatol. 2016;13 (11):630-632.
17. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012;18(4):472-477.
18. AstraZeneca. Bydureon (exenatide) extended release prescribing information. 2012; https://www .accessdata.fda.gov/drugsatfda-docs/nda/2014 /022200Orig1s008.pdf. Accessed June 6, 2017.
19. GlaxoSmithKline. Tanzeum (albiglutide) extended release prescribing information. 2015; https://www.gsksource.com/pharma/content /dam/GlaxoSmithKline/US/en/Prescribing -Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU -COMBINED.PDF. Accessed June 6, 2017.
20. Eli Lilly. Trulicity (dulaglutide) extended release prescribing information. 2014; http://pi.lilly.com/us /trulicity-uspi.pdf. Accessed June 6, 2017.